Development of D-melittin polymeric nanoparticles for anti-cancer treatment

Lv, Shixian; Sylvestre, Meilyn; Song, Kefan; Pun, Suzie H.

doi:10.1016/j.biomaterials.2021.121076

Cited by 39 publications

(21 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach has been successfully used in generating gramicidin S and melittin analogs with only antibacterial activity without any hemolytic activity 35 , 36 . In order to prevent off-target toxic effects of melittin, formulations with polymeric nanoparticles are being explored 37 . Formulations for use of peptides as therapeutics is a challenge but there are considerable efforts towards this goal 12 .…”

Section: Discussionmentioning

confidence: 99%

Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection

Enayathullah

Parekh

Banu

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The COVID19 pandemic has led to multipronged approaches for treatment of the disease. Since de novo discovery of drugs is time consuming, repurposing of molecules is now considered as one of the alternative strategies to treat COVID19. Antibacterial peptides are being recognized as attractive candidates for repurposing to treat viral infections. In this study, we describe the anti-SARS-CoV-2 activity of the well-studied antibacterial peptides gramicidin S and melittin obtained from Bacillus brevis and bee venom respectively. The EC50 values for gramicidin S and melittin were 1.571 µg and 0.656 µg respectively based on in vitro antiviral assay. Significant decrease in the viral load as compared to the untreated group with no/very less cytotoxicity was observed. Both the peptides treated to the SARS-CoV-2 infected Vero cells showed viral clearance from 12 h onwards with a maximal viral clearance after 24 h post infection. Proteomics analysis indicated that more than 250 proteins were differentially regulated in the gramicidin S and melittin treated SARS-CoV-2 infected Vero cells against control SARS-CoV-2 infected Vero cells after 24 and 48 h post infection. The identified proteins were found to be associated in the metabolic and mRNA processing of the Vero cells post-treatment and infection. Both these peptides could be attractive candidates for repurposing to treat SARS-CoV-2 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection

Enayathullah

Parekh

Banu

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Multiple stimulus-responsive nano delivery systems have been used to deliver MEL to attenuate the cytotoxicity of MEL during systemic circulation and to achieve its targeted delivery, including pH-responsive [ 101 , 102 , 103 ], magnetic-responsive [ 84 ], photosensitive [ 103 , 104 ] and redox-sensitive [ 105 ] delivery systems. The stimulus-responsive carrier maintains a stable state during circulation in the body and is stimulated and changes conformation or structure when the nanocarrier reaches the target site and releases MEL to a therapeutic concentration [ 84 , 101 , 104 ].…”

Section: Delivery Vehicles For Melittinmentioning

confidence: 99%

Melittin-Based Nano-Delivery Systems for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Melittin (MEL) is a 26-amino acid polypeptide with a variety of pharmacological and toxicological effects, which include strong surface activity on cell lipid membranes, hemolytic activity, and potential anti-tumor properties. However, the clinical application of melittin is restricted due to its severe hemolytic activity. Different nanocarrier systems have been developed to achieve stable loading, side effects shielding, and tumor-targeted delivery, such as liposomes, cationic polymers, lipodisks, etc. In addition, MEL can be modified on nano drugs as a non-selective cytolytic peptide to enhance cellular uptake and endosomal/lysosomal escape. In this review, we discuss recent advances in MEL’s nano-delivery systems and MEL-modified nano drug carriers for cancer therapy.

show abstract

“…In recent years, exogenous nanoparticles, which can act as carriers for novel genes and drugs, have attracted wide attention [ 134 ]. Compared with traditional treatments, nanoparticles can reduce the concentration of a drug needed to induce effects that are otherwise only achieved with a high drug or radiation dose while increasing drug distribution in target organs and avoiding systemic damage [ 135 ]. Another emerging approach for targeting circRNAs is exosomes, which are defined as microvesicles with diameters of 30–100 nm that can be released from cells to exert intercellular communication functions [ 136 ].…”

Section: Future Perspectivementioning

confidence: 99%

Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star

Chen

Shen

et al. 2022

Cell Biosci

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a highly malignant solid tumor with insidious onset and easy early metastasis. Despite tremendous efforts devoted to research in this field, the mechanisms underlying PC tumorigenesis and progression remain unclear. Additionally, robust biomarkers and satisfactory therapeutic strategies for clinical use in PC patients are still lacking. Circular RNAs (circRNAs) are a new type of non-coding RNA originating from precursor messenger RNAs, with a covalent continuous closed-loop structure, strong stability and high specificity. Accumulating evidence suggests that circRNAs may participate in PC development and progression. Abnormal expression of circRNAs in PC is considered a vital factor that affects tumor cell proliferation, migration, invasion, apoptosis, angiogenesis and drug resistance. In this review of relevant articles published in recent years, we describe the basic knowledge concerning circRNAs, including their classification, biogenesis, functions and research approaches. Moreover, the biological roles and clinical significance of circRNAs related to PC are discussed. Finally, we note the questions remaining from recent studies and anticipate that further investigations will address these gaps in knowledge in this field. In conclusion, we expect to provide insights into circRNAs as potential targets for specific PC diagnosis and treatment in the future.

show abstract

Development of D-melittin polymeric nanoparticles for anti-cancer treatment

Cited by 39 publications

References 55 publications

Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection

Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection

Melittin-Based Nano-Delivery Systems for Cancer Therapy

Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star

Contact Info

Product

Resources

About